sildenafil and Fibrosis

sildenafil has been researched along with Fibrosis* in 1 studies

Other Studies

1 other study(ies) available for sildenafil and Fibrosis

Article	Year
Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. Journal of medicinal chemistry, 2021, 07-08, Volume: 64, Issue:13 Hepatic fibrosis commonly exists in chronic liver disease and would eventually develop to cirrhosis and liver cancer with high fatality. Phosphodiesterase-9 (PDE9) has attracted profound attention as a drug target because of its highest binding affinity among phosphodiesterases (PDEs) with cyclic guanosine monophosphate. However, no published study has reported PDE9 inhibitors as potential agents against hepatic fibrosis yet. Herein, structural modification from a starting hit Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Bile Ducts; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Fibrosis; Humans; Molecular Structure; Phosphodiesterase Inhibitors; Rats; Structure-Activity Relationship	2021

Article

Year

Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.

Journal of medicinal chemistry, 2021, 07-08, Volume: 64, Issue:13

Hepatic fibrosis commonly exists in chronic liver disease and would eventually develop to cirrhosis and liver cancer with high fatality. Phosphodiesterase-9 (PDE9) has attracted profound attention as a drug target because of its highest binding affinity among phosphodiesterases (PDEs) with cyclic guanosine monophosphate. However, no published study has reported PDE9 inhibitors as potential agents against hepatic fibrosis yet. Herein, structural modification from a starting hit

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Bile Ducts; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Fibrosis; Humans; Molecular Structure; Phosphodiesterase Inhibitors; Rats; Structure-Activity Relationship

2021